Summit Therapeutics plc
(“Summit” or the “Company”)
SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER AND HALF YEAR ENDED 31 JULY 2017 ON 31 AUGUST 2017
Oxford, UK, · August 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the second quarter and half year ended 31 July 2017 on 31 August 2017.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the second quarter and half year results press release and a replay of the call will also be available through the Company’s website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit Therapeutics |
Tel: +44 (0)1235 443 951 |
Cairn Financial Advisers LLP |
Tel: +44 (0)20 7213 0880 |
N+1 Singer
|
Tel: +44 (0)20 7496 3000 |
MacDougall Biomedical Communications | Tel: +1 781 235 3060 ksharma@macbiocom.com
|
| Consilium Strategic Communications (Financial public relations, UK) Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Lindsey Neville | Tel: +44 (0)20 3709 5700 summit@consilium-comms.com |
-END-
